Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 633 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07731191Recruiting
Digital tools to predict Alzheimer's risk factors
This study uses smartphone tools to track early signs of Alzheimer's by analyzing risk factors. It is for people with mild cognitive issues (MCI) or subjective cognitive decline (SCD) who do not have dementia.
Brescia, BSAges 18 years+ - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Irvine, CaliforniaAges 55–80 - NCT07717567Recruiting
Blood tests to diagnose and predict Alzheimer's disease
This study is testing whether a simple blood test can help diagnose Alzheimer's disease and predict how the disease will progress. If you have memory or thinking problems that have been getting worse, you may be able to join.
Milan, MilanoAges 40 years+ - NCT07701161Recruiting
At-home blood test for Alzheimer's disease
This study is developing a simple finger-prick test you can do at home to measure a blood marker related to Alzheimer's disease. It aims to make checking for Alzheimer's easier and more convenient.
Chicago, IllinoisAges 40–90 - NCT07694921Enrolling by invitation
Non-invasive brain stimulation for Alzheimer's disease
This trial tests if a safe, non-invasive electrical stimulation can help people with Alzheimer's disease. It aims to improve thinking and memory skills.
Hangzhou, ZhejiangAges 60 years+ - NCT07688460RecruitingPhase 4
Blood test to monitor Alzheimer's drug Lecanemab
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Yiwu, ZhejiangAges 50–90 - NCT07679906Recruiting
Nationwide digital study for Alzheimer’s prevention and trial readiness
This study uses a saliva sample and online tools to see if you have a genetic risk factor for Alzheimer’s. It aims to build a large group of people who may be at higher risk, so they can be invited to future prevention trials.
HuningueAges 45 years+ - NCT07672171Recruiting
Far-infrared therapy for Alzheimer's dementia
This study tests whether far-infrared therapy (a gentle heat treatment) can help people with Alzheimer's dementia. If you have mild-to-moderate Alzheimer's on medication, you may be able to join.
TaipeiAges 61–92 - NCT07666113Recruiting
Blood test for Alzheimer's disease detection in primary care
This study tests whether a simple blood test can help detect Alzheimer's disease in people who visit their primary care doctor with memory concerns. It aims to improve early diagnosis at the community level.
LeuvenAges 55–85 - NCT07659964Recruiting
Rhythmic music and walking study for Alzheimer's
This study tests whether listening to a steady beat (rhythmic music) while walking can improve movement and brain function in people with mild Alzheimer's disease. Healthy volunteers are also needed for comparison.
Boston, MassachusettsAges 50–90 - NCT07651319RecruitingPhase 1/Phase 2
IL-2 and Semaglutide Treatment for Alzheimer's Disease
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
Houston, TexasAges 50–86 - NCT07646054Enrolling by invitation
Lifestyle coaching for preventing Alzheimer's in APOE4 carriers
This study tests a digital lifestyle coaching program designed to help prevent Alzheimer's disease in people who carry the APOE4 genetic variant, which increases risk. Over one year, you'll get personalized health coaching through apps and possibly a smart ring to track your progress.
La Jolla, CaliforniaAges 60–80 - NCT07636811RecruitingPhase 2
Mivelsiran for Early Alzheimer's in Down Syndrome
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
Maitland, FloridaAges 40–55 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Irvine, CaliforniaAges 50 years+ - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT03890861Recruiting
Exercise program to help lower Alzheimer’s risk
This trial studies whether a structured group exercise program can help lower Alzheimer’s disease risk in older African Americans. You would be assigned to a group by chance and asked to attend regular sessions if it’s safe for you to exercise.
Baton Rouge, LouisianaAges 60 years+ - NCT07618481Recruiting
Brain Stimulation Study for Alzheimer's Disease
This study tests whether a special type of brain stimulation called 40Hz BCI (brain-computer interface) might help slow memory loss in people with Alzheimer's disease. You would receive daily stimulation sessions at home with help from a caregiver.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT07598370RecruitingPhase 1
Testing LY3439539 for early-stage Alzheimer's disease
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Irvine, CaliforniaAges 50–85 - NCT07598617Recruiting
Testing a New Computer Memory Assessment for Early Cognitive Changes
This study evaluates a new computer-based test to detect early memory and thinking changes before they progress to dementia. Researchers are looking for adults 65+ who've noticed subtle cognitive changes in the last 5 years to help refine and test this assessment tool.
Plymouth, DevonAges 65 years+ - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT07570719Recruiting
Community screening for early Alzheimer's disease signs
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
Shanghai, Shanghai MunicipalityAges 60–80 - NCT07573982Recruiting
Ultrasound brain treatment for early memory loss
This study tests a special ultrasound treatment that may help clear harmful brain waste linked to Alzheimer's. You would receive the treatment in six short sessions, and the researchers will check your memory and brain health to see if it helps.
Stanford, CaliforniaAges 18 years+ - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 633 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.